English

PLIANT THERAPEUTICS, INC.

EDGAR

PLRX Quarterly report (10-Q) · filed 2026-08-11

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-47.7 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -155503000 USD Source
Operating Cash Flow: -107841000 USD Source

Free cash flow

-47.9 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -155503000 USD Source
Operating Cash Flow: -107841000 USD Source
Capital Expenditure: 3848000 USD Source
Capital Expenditure: 3639000 USD Source

Cash and cash equivalents: 24.9 million USD 2026-06-30 Source
Exact value

24883000 USD
Long-term debt including current maturities: 0 USD 2026-06-30 Source
Exact value

0 USD
Shares outstanding: 61.9 million shares 2026-06-30 Source
Exact value

61920154 shares

Reported share-count change

0.87% · 534 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

61386183 shares · 2025-06-30· Source
61920154 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Revenue: 0 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 0 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 0 USD · 2024-07-01 – 2024-09-30 Source
Revenue: 0 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 0 USD · 2024-01-01 – 2024-09-30 Source

Net income

-92.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -26301000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -149344000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -125767000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -20040000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -22371000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-70.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -110548000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -89467000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -128336000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -110548000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -19229000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -32026000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -19229000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

0 USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 374000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 374000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 374000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 374000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-70.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -110548000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -89467000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -128336000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -110548000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -19229000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -32026000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -19229000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 374000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 374000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 374000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 374000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2025-12-31
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#922488 Filing: 000174647326000037 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#923377 Filing: 000174647326000037
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 60.96 million

Prior period

−USD 210.3 million

2024-01-01 – 2024-12-31
Current period

−USD 149.34 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-149344000 − -210304000 = 60960000 USD

-210304000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-149344000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Year-over-year change in Net income: 60960000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -149344000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#997157 Filing: 000174647326000037 Input fundies:NetIncome: -210304000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#997929 Filing: 000174647326000037
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 27.17 million

Prior period

−USD 155.5 million

2024-01-01 – 2024-12-31
Current period

−USD 128.34 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-128336000 − -155503000 = 27167000 USD

-155503000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-128336000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Year-over-year change in Operating cash flow: 27167000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -128336000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1014854 Filing: 000174647326000037 Input fundies:OperatingCashFlow: -155503000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1015506 Filing: 000174647326000037
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-90.3%

Prior period

USD 3.85 million

2024-01-01 – 2024-12-31
Current period

USD 374,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

374000 − 3848000 = -3474000 USD

3848000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
374000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Year-over-year change in Capital expenditure: -3474000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 374000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1019660 Filing: 000174647326000037 Input fundies:CapitalExpenditure: 3848000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1020218 Filing: 000174647326000037
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 156.37 million
Operating income −USD 156.37 million
Tax, interest and other Derived −USD 7.03 million
Net income −USD 149.34 million

Cash

Operating cash flow −USD 128.34 million
Capital expenditure USD 374,000
Free cash flow Derived −USD 128.71 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 102% of revenue.
2020 Operating loss: operating costs were 200% of revenue.
2021 Operating loss: operating costs were 1,388% of revenue.
2022 Operating loss: operating costs were 1,413% of revenue.
2023 Operating loss: operating costs were 11,755% of revenue.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	57052000	58283000 Derived	-1231000	-600000 Derived	-631000	-3714000 Derived	Source 2019-01-01 – 2019-12-31: 57052000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -1231000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -631000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -2750000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 964000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	41817000	83462000 Derived	-41645000	-112000 Derived	-41533000	-38803000 Derived	Source 2020-01-01 – 2020-12-31: 41817000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -41645000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -41533000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -37271000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1532000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	7572000	105107000 Derived	-97535000	-272000 Derived	-97263000	-77396000 Derived	Source 2021-01-01 – 2021-12-31: 7572000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -97535000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -97263000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -75443000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1953000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	9685000	136885000 Derived	-127200000	-3879000 Derived	-123321000	-96391000 Derived	Source 2022-01-01 – 2022-12-31: 9685000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -127200000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -123321000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -94631000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1760000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1580000	185725000 Derived	-184145000	-22809000 Derived	-161336000	-117282000 Derived	Source 2023-01-01 – 2023-12-31: 1580000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -184145000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -161336000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -116361000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 921000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	228365000 Derived	-228365000	-18061000 Derived	-210304000	-159351000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -228365000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -210304000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -155503000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3848000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	156373000 Derived	-156373000	-7029000 Derived	-149344000	-128710000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -156373000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -149344000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -128336000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 374000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	57052000	Revenue: 57052000 Open source
20202020-12-31	Revenue	41817000	Revenue: 41817000 Open source
20212021-12-31	Revenue	7572000	Revenue: 7572000 Open source
20222022-12-31	Revenue	9685000	Revenue: 9685000 Open source
20232023-12-31	Revenue	1580000	Revenue: 1580000 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 57052000 Open source
20202020-12-31	Year over year	-26.7%	Revenue: 41817000 Open source Revenue: 57052000 Open source
20212021-12-31	Year over year	-81.9%	Revenue: 7572000 Open source Revenue: 41817000 Open source
20222022-12-31	Year over year	27.9%	Revenue: 9685000 Open source Revenue: 7572000 Open source
20232023-12-31	Year over year	-83.7%	Revenue: 1580000 Open source Revenue: 9685000 Open source
20242024-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 1580000 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -11,654.7% 2023

Net margin -10,211.1% 2023

Free cash flow margin -7,422.9% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-2.2%	Operating Income: -1231000 Open source Revenue: 57052000 Open source
20202020-12-31	Operating margin	-99.6%	Operating Income: -41645000 Open source Revenue: 41817000 Open source
20212021-12-31	Operating margin	-1,288.1%	Operating Income: -97535000 Open source Revenue: 7572000 Open source
20222022-12-31	Operating margin	-1,313.4%	Operating Income: -127200000 Open source Revenue: 9685000 Open source
20232023-12-31	Operating margin	-11,654.7%	Operating Income: -184145000 Open source Revenue: 1580000 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -228365000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -156373000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	-1.1%	Net Income: -631000 Open source Revenue: 57052000 Open source
20202020-12-31	Net margin	-99.3%	Net Income: -41533000 Open source Revenue: 41817000 Open source
20212021-12-31	Net margin	-1,284.5%	Net Income: -97263000 Open source Revenue: 7572000 Open source
20222022-12-31	Net margin	-1,273.3%	Net Income: -123321000 Open source Revenue: 9685000 Open source
20232023-12-31	Net margin	-10,211.1%	Net Income: -161336000 Open source Revenue: 1580000 Open source
20242024-12-31	Net margin	Not reported	Net Income: -210304000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	Not reported	Net Income: -149344000 Open source Revenue: 0 Open source
20192019-12-31	Free cash flow margin	-6.5%	Revenue: 57052000 Open source Operating Cash Flow: -2750000 Open source Capital Expenditure: 964000 Open source
20202020-12-31	Free cash flow margin	-92.8%	Revenue: 41817000 Open source Operating Cash Flow: -37271000 Open source Capital Expenditure: 1532000 Open source
20212021-12-31	Free cash flow margin	-1,022.1%	Revenue: 7572000 Open source Operating Cash Flow: -75443000 Open source Capital Expenditure: 1953000 Open source
20222022-12-31	Free cash flow margin	-995.3%	Revenue: 9685000 Open source Operating Cash Flow: -94631000 Open source Capital Expenditure: 1760000 Open source
20232023-12-31	Free cash flow margin	-7,422.9%	Revenue: 1580000 Open source Operating Cash Flow: -116361000 Open source Capital Expenditure: 921000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -155503000 Open source Capital Expenditure: 3848000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -128336000 Open source Capital Expenditure: 374000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -128.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-2750000	Operating Cash Flow: -2750000 Open source
20202020-12-31	Operating cash flow	-37271000	Operating Cash Flow: -37271000 Open source
20212021-12-31	Operating cash flow	-75443000	Operating Cash Flow: -75443000 Open source
20222022-12-31	Operating cash flow	-94631000	Operating Cash Flow: -94631000 Open source
20232023-12-31	Operating cash flow	-116361000	Operating Cash Flow: -116361000 Open source
20242024-12-31	Operating cash flow	-155503000	Operating Cash Flow: -155503000 Open source
20252025-12-31	Operating cash flow	-128336000	Operating Cash Flow: -128336000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -128.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-3714000	Operating Cash Flow: -2750000 Open source Capital Expenditure: 964000 Open source
20202020-12-31	Free cash flow	-38803000	Operating Cash Flow: -37271000 Open source Capital Expenditure: 1532000 Open source
20212021-12-31	Free cash flow	-77396000	Operating Cash Flow: -75443000 Open source Capital Expenditure: 1953000 Open source
20222022-12-31	Free cash flow	-96391000	Operating Cash Flow: -94631000 Open source Capital Expenditure: 1760000 Open source
20232023-12-31	Free cash flow	-117282000	Operating Cash Flow: -116361000 Open source Capital Expenditure: 921000 Open source
20242024-12-31	Free cash flow	-159351000	Operating Cash Flow: -155503000 Open source Capital Expenditure: 3848000 Open source
20252025-12-31	Free cash flow	-128710000	Operating Cash Flow: -128336000 Open source Capital Expenditure: 374000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

19.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	7.6%	Total Liabilities: 9084000 Open source Total Assets: 119064000 Open source
20202020-12-31	Liabilities / assets	4.2%	Total Liabilities: 12465000 Open source Total Assets: 295526000 Open source
20212021-12-31	Liabilities / assets	10%	Total Liabilities: 22156000 Open source Total Assets: 221215000 Open source
20222022-12-31	Liabilities / assets	10.6%	Total Liabilities: 37271000 Open source Total Assets: 350613000 Open source
20232023-12-31	Liabilities / assets	7.5%	Total Liabilities: 38578000 Open source Total Assets: 512154000 Open source
20242024-12-31	Liabilities / assets	23.4%	Total Liabilities: 92868000 Open source Total Assets: 396949000 Open source
20252025-12-31	Liabilities / assets	19.5%	Total Liabilities: 44023000 Open source Total Assets: 225228000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

12× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	13.69×	Current Assets: 111900000 Open source Current Liabilities: 8172000 Open source
20202020-12-31	Current assets / current liabilities	25.07×	Current Assets: 290754000 Open source Current Liabilities: 11599000 Open source
20212021-12-31	Current assets / current liabilities	12.44×	Current Assets: 209441000 Open source Current Liabilities: 16831000 Open source
20222022-12-31	Current assets / current liabilities	14.23×	Current Assets: 340311000 Open source Current Liabilities: 23913000 Open source
20232023-12-31	Current assets / current liabilities	17.72×	Current Assets: 505502000 Open source Current Liabilities: 28524000 Open source
20242024-12-31	Current assets / current liabilities	10.91×	Current Assets: 362264000 Open source Current Liabilities: 33218000 Open source
20252025-12-31	Current assets / current liabilities	12×	Current Assets: 196448000 Open source Current Liabilities: 16365000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 631,000 Exact value Exact value: -631000 USD 2019-01-01 – 2019-12-31: -631000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PLIANT THERAPEUTICS, INC. · 2019-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Net Income: -631000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -631000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#2295044 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.	−USD 2.75 million Exact value Exact value: -2750000 USD 2019-01-01 – 2019-12-31: -2750000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PLIANT THERAPEUTICS, INC. · 2019-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Operating Cash Flow: -2750000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2750000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1622171 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.	USD 964,000 Exact value Exact value: 964000 USD 2019-01-01 – 2019-12-31: 964000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PLIANT THERAPEUTICS, INC. · 2019-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Capital Expenditure: 964000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 964000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1635583 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.	−USD 3.71 million Calculation and evidence -2750000 − 964000 USD Exact free cash flow: -3714000 USD 2019-01-01 – 2019-12-31: -2750000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 964000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PLIANT THERAPEUTICS, INC. · 2019-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Free cash flow: -3714000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2750000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1622171 Filing: 000174647322000010 Input fundies:CapitalExpenditure: 964000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1635583 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 41.53 million Exact value Exact value: -41533000 USD 2020-01-01 – 2020-12-31: -41533000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PLIANT THERAPEUTICS, INC. · 2020-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Net Income: -41533000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41533000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#2293868 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.	−USD 37.27 million Exact value Exact value: -37271000 USD 2020-01-01 – 2020-12-31: -37271000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PLIANT THERAPEUTICS, INC. · 2020-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Operating Cash Flow: -37271000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37271000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1621115 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.	USD 1.53 million Exact value Exact value: 1532000 USD 2020-01-01 – 2020-12-31: 1532000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PLIANT THERAPEUTICS, INC. · 2020-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Capital Expenditure: 1532000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1532000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1634595 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.	−USD 38.8 million Calculation and evidence -37271000 − 1532000 USD Exact free cash flow: -38803000 USD 2020-01-01 – 2020-12-31: -37271000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1532000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PLIANT THERAPEUTICS, INC. · 2020-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Free cash flow: -38803000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37271000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1621115 Filing: 000174647322000010 Input fundies:CapitalExpenditure: 1532000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000010/plrx-20211231.htm#1634595 Filing: 000174647322000010 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 97.26 million Exact value Exact value: -97263000 USD 2021-01-01 – 2021-12-31: -97263000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PLIANT THERAPEUTICS, INC. · 2021-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Net Income: -97263000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -97263000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000043/plrx-20231231.htm#1100332 Filing: 000174647324000043 The citation records this snapshot. The page link may show a newer release later.	−USD 75.44 million Exact value Exact value: -75443000 USD 2021-01-01 – 2021-12-31: -75443000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PLIANT THERAPEUTICS, INC. · 2021-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Operating Cash Flow: -75443000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -75443000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000043/plrx-20231231.htm#1123530 Filing: 000174647324000043 The citation records this snapshot. The page link may show a newer release later.	USD 1.95 million Exact value Exact value: 1953000 USD 2021-01-01 – 2021-12-31: 1953000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PLIANT THERAPEUTICS, INC. · 2021-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Capital Expenditure: 1953000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1953000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000043/plrx-20231231.htm#1130254 Filing: 000174647324000043 The citation records this snapshot. The page link may show a newer release later.	−USD 77.4 million Calculation and evidence -75443000 − 1953000 USD Exact free cash flow: -77396000 USD 2021-01-01 – 2021-12-31: -75443000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1953000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PLIANT THERAPEUTICS, INC. · 2021-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Free cash flow: -77396000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -75443000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000043/plrx-20231231.htm#1123530 Filing: 000174647324000043 Input fundies:CapitalExpenditure: 1953000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000043/plrx-20231231.htm#1130254 Filing: 000174647324000043 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 123.32 million Exact value Exact value: -123321000 USD 2022-01-01 – 2022-12-31: -123321000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PLIANT THERAPEUTICS, INC. · 2022-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Net Income: -123321000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -123321000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1104490 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.	−USD 94.63 million Exact value Exact value: -94631000 USD 2022-01-01 – 2022-12-31: -94631000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PLIANT THERAPEUTICS, INC. · 2022-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Operating Cash Flow: -94631000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -94631000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1127678 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.	USD 1.76 million Exact value Exact value: 1760000 USD 2022-01-01 – 2022-12-31: 1760000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PLIANT THERAPEUTICS, INC. · 2022-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Capital Expenditure: 1760000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1760000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1134402 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.	−USD 96.39 million Calculation and evidence -94631000 − 1760000 USD Exact free cash flow: -96391000 USD 2022-01-01 – 2022-12-31: -94631000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1760000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PLIANT THERAPEUTICS, INC. · 2022-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Free cash flow: -96391000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -94631000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1127678 Filing: 000174647325000054 Input fundies:CapitalExpenditure: 1760000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1134402 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 161.34 million Exact value Exact value: -161336000 USD 2023-01-01 – 2023-12-31: -161336000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PLIANT THERAPEUTICS, INC. · 2023-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Net Income: -161336000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -161336000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1103708 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.	−USD 116.36 million Exact value Exact value: -116361000 USD 2023-01-01 – 2023-12-31: -116361000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PLIANT THERAPEUTICS, INC. · 2023-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Operating Cash Flow: -116361000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -116361000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1127021 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.	USD 921,000 Exact value Exact value: 921000 USD 2023-01-01 – 2023-12-31: 921000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PLIANT THERAPEUTICS, INC. · 2023-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Capital Expenditure: 921000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 921000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1133839 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.	−USD 117.28 million Calculation and evidence -116361000 − 921000 USD Exact free cash flow: -117282000 USD 2023-01-01 – 2023-12-31: -116361000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 921000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PLIANT THERAPEUTICS, INC. · 2023-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Free cash flow: -117282000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -116361000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1127021 Filing: 000174647325000054 Input fundies:CapitalExpenditure: 921000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000054/plrx-20241231.htm#1133839 Filing: 000174647325000054 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 210.3 million Exact value Exact value: -210304000 USD 2024-01-01 – 2024-12-31: -210304000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PLIANT THERAPEUTICS, INC. · 2024-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Net Income: -210304000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -210304000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#997929 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.	−USD 155.5 million Exact value Exact value: -155503000 USD 2024-01-01 – 2024-12-31: -155503000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PLIANT THERAPEUTICS, INC. · 2024-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Operating Cash Flow: -155503000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -155503000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1015506 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.	USD 3.85 million Exact value Exact value: 3848000 USD 2024-01-01 – 2024-12-31: 3848000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PLIANT THERAPEUTICS, INC. · 2024-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Capital Expenditure: 3848000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3848000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1020218 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.	−USD 159.35 million Calculation and evidence -155503000 − 3848000 USD Exact free cash flow: -159351000 USD 2024-01-01 – 2024-12-31: -155503000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3848000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PLIANT THERAPEUTICS, INC. · 2024-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Free cash flow: -159351000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -155503000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1015506 Filing: 000174647326000037 Input fundies:CapitalExpenditure: 3848000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1020218 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 149.34 million Exact value Exact value: -149344000 USD 2025-01-01 – 2025-12-31: -149344000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Net Income: -149344000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -149344000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#997157 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.	−USD 128.34 million Exact value Exact value: -128336000 USD 2025-01-01 – 2025-12-31: -128336000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Operating Cash Flow: -128336000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -128336000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1014854 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.	USD 374,000 Exact value Exact value: 374000 USD 2025-01-01 – 2025-12-31: 374000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Capital Expenditure: 374000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 374000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1019660 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.	−USD 128.71 million Calculation and evidence -128336000 − 374000 USD Exact free cash flow: -128710000 USD 2025-01-01 – 2025-12-31: -128336000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 374000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PLIANT THERAPEUTICS, INC. · 2025-12-31 PLIANT THERAPEUTICS, INC. (edgar:1746473) Free cash flow: -128710000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:13:39Z Snapshot: 3e3aabca15f7b0bd90401900a42c27ae154ea20a2c964524b73eeec28d77a871 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1746473?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -128336000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1014854 Filing: 000174647326000037 Input fundies:CapitalExpenditure: 374000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm#1019660 Filing: 000174647326000037 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

30 filings · 1,811 latest values · 1,811 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001746473, 1746473, PLRX, edgar:1746473

Also known as PLIANT THERAPEUTICS, INC.

PLIANT THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation